➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Boehringer Ingelheim
Mallinckrodt
Medtronic
Express Scripts

Last Updated: October 21, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,702,997

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,702,997 protect, and when does it expire?

Patent 6,702,997 protects ACCUNEB and is included in one NDA.

This patent has twelve patent family members in eight countries.

Summary for Patent: 6,702,997
Title: Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
Abstract:The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.
Inventor(s): Chaudry; Imtiaz (Napa, CA), Banerjee; Partha (San Ramon, CA)
Assignee: Dey, L.P. (Napa, CA)
Application Number:10/034,829
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,702,997
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 6,702,997

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Mylan Speciality Lp ACCUNEB albuterol sulfate SOLUTION;INHALATION 020949-002 Apr 30, 2001 AN RX Yes Yes   Start Trial   Start Trial INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)   Start Trial
Mylan Speciality Lp ACCUNEB albuterol sulfate SOLUTION;INHALATION 020949-001 Apr 30, 2001 AN RX Yes Yes   Start Trial   Start Trial INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Express Scripts
Boehringer Ingelheim
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.